VIZIOBLOK

Quốc gia: Ai-len

Ngôn ngữ: Tiếng Anh

Nguồn: HPRA (Health Products Regulatory Authority)

Thành phần hoạt chất:

TIMOLOL MALEATE

Sẵn có từ:

Pharmathen S.A.

Mã ATC:

S01ED01

INN (Tên quốc tế):

TIMOLOL MALEATE

Liều dùng:

2.5 Mg/Ml

Dạng dược phẩm:

Eye Drops Solution

Loại thuốc theo toa:

Product subject to prescription which may be renewed (B)

Khu trị liệu:

timolol

Tình trạng ủy quyền:

Not Marketed

Ngày ủy quyền:

2016-09-16

Đặc tính sản phẩm

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Vizioblok 2.5 mg/ml Eye Drops Solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml of Vizioblok 2.5 mg/ml solution contains 3.417 mg of timolol
maleate (equivalent to 2.5 mg of timolol).
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Eye drops, solution
Clear, colourless, eye drops
pH: 6.5-7.5
Osmolality: 270-330 mOsm/kg
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Visioblok Eye Drops Solution is a beta-adrenoreceptor blocking agent
used topically in the reduction of elevated intra-
ocular pressure in various conditions.
Visioblok is indicated in adult patients with ocular hypertension;
adult patients with chronic open-angle glaucoma
including aphakic patients; some adult patients with secondary
glaucoma.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Adults:
_Posology:_
Recommended therapy is one drop of 2.5 mg/ml solution in the affected
eye, once or twice (morning and evening) a
day.
When using nasolacrimal occlusion or closing the eyelids for 2
minutes, the systemic absorption is reduced. This may
result in a decrease in systemic side effects and an increase in local
activity.
If clinical response is not adequate, dosage may be changed to one
drop of 5 mg/ml solution in each affected eye, once
or twice (morning and evening) a day. If needed, Visioblok may be used
with other agent(s) for lowering intra-ocular
pressure. The use of two topical beta-adrenergic blocking agents is
not recommended (see 4.4).
Intra-ocular pressure should be reassessed approximately four weeks
after starting treatment because response to
Visioblok may take a few weeks to stabilise.
Provided that the intra-ocular pressure is maintained at satisfactory
levels, many patients can then be placed on once-a-
day therapy of Visioblok.
_Transfer from other agents_
When another topical beta-blocking agent is being used, discontinue
its use after a full day of therapy and start
treatment with Visioblok the next day with one drop of 2.5 mg/ml
Visio